Sage Journals: Discover world-class research

Abstract

Background:

Hypophonia is a prevailing problem in people with multiple sclerosis (PwMS). However, evidence supporting the effectiveness of voice rehabilitation is lacking.

Objective:

The aim of this study was to identify the most effective method to reduce hypophonia.

Methods:

In this randomized controlled trial, 44 PwMS were randomized to intensive and high-effort voice treatment groups, the LSVT-LOUD^®, and conventional treatment group. Subjects received 16 treatments (4 sessions/week) lasting 45 minutes. The primary outcome was voice intensity (dB) in monologue, vocalization, and sentences while voice handicap index (VHI) measured voice self-perception. Outcomes were assessed by a blinded observer at baseline, post-treatment, and 15-month follow-up (FU).

Results:

Linear models revealed a significant post-intervention between-group mean difference in favor of LSVT-LOUD for monologue: +6.3 dB (95% CI: 2.5 to 10.1); vocalization: +7.4 dB (95% CI: 2.3 to 12.5); and sentences: +9.5 dB (95% CI: 4.7 to 14.3). However, 43.7% PwMS in the LSVT-LOUD and 10% in the conventional treatment group obtained a full recovery of voice intensity (>60 dB) post-treatment, Fisher’s test = 13.3, p < 0.01. However, these improvements were not maintained at FU. Between-group differences at VHI were −10.8 (95% CI: −21.2 to −0.4) and −11.3 (95% CI: −24.3 to −1.7) in favor of LSVT-LOUD at post and FU.

Conclusion:

LSVT-LOUD can be a valid treatment to increase voice intensity in PwMS. However, results suggest the need for FU interventions targeting maintenance.

Keywords

Multiple sclerosis voice speech and language therapy acoustic outcomes

Get full access to this article

View all access options for this article.

References

Noonan

Williamson

Henry

, et al. The prevalence of multiple sclerosis in 3 US communities. Prev Chronic Dis 2010; 7(1): A12.

Hartelius

Runmarker

Andersen

Prevalence and characteristics of dysarthria in a multiple-sclerosis incidence cohort: Relation to neurological data. Folia Phoniatr Logop 2000; 52(4): 160–177.

Noffs

Perera

Kolbe

, et al. What speech can tell us: A systematic review of dysarthria characteristics in multiple sclerosis. Autoimmun Rev 2018; 17(12): 1202–1209.

Taveira

Teixeira

Domingues

RB.

Early respiratory evaluation should be carried out systematically in patients with multiple sclerosis. Arq Neuropsiquiatr 2013; 71(3): 142–145.

Dogan

Midi

Yazici

, et al. Objective and subjective evaluation of voice quality in multiple sclerosis. J Voice 2007; 21(6): 735–740.

Sackley

Smith

Rick

, et al. Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson’s disease: A pilot randomised controlled trial (PD COMM pilot). Pilot Feasibility Stud 2018; 4: 30.

Bauer

Aleric

Jancic

Comparing voice self-assessment with auditory perceptual analysis in patients with multiple sclerosis. Int Arch Otorhinolaryngol 2015; 19(2): 100–105.

Tjaden

Watling

Characteristics of diadochokinesis in multiple sclerosis and Parkinson’s disease. Folia Phoniatr Logop 2003; 55(5): 241–259.

Hartelius

Nord

Wising

Speech modification in dysarthria associated with multiple sclerosis; an intervention based on vocal efficiency, contrastive stress and verbal repair strategies. J Med Speech Lang Pathol 1997; 5(2): 52.

10.

Sapir

Spielman

Ramig

, et al. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on ataxic dysarthria: A case study. Am J Speech Lang Pathol 2003; 12(4): 387–399.

11.

Chiara

Martin

Sapienza

Expiratory muscle strength training: Speech production outcomes in patients with multiple sclerosis. Neurorehabil Neural Repair 2007; 21(3): 239–249.

12.

Nordio

Bernitsas

Meneghello

, et al. Expiratory and phonation times as measures of disease severity in patients with multiple sclerosis. Mult Scler Relat Disord 2018; 23: 27–32.

13.

Baldanzi

Crispiatico

Foresti

, et al. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT LOUD]) in subjects with multiple sclerosis: A pilot study. J Voice. Epub ahead of print 18 August 2020. DOI: 10.1016/j.jvoice.2020.07.025.

14.

Fox

Ramig

Ciucci

, et al. The science and practice of LSVT/LOUD: Neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders. Semin Speech Lang 2006; 27(4): 283–299.

15.

Moher

Hopewell

Schulz

, et al. CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. Int J Surg 2012; 10(1): 28–55.

16.

Thompson

Banwell

Barkhof

, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17(2): 162–173.

17.

Folstein

McHugh

PR.

“Mini mental state” a practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res 1975; 12(3): 189–198.

18.

Hacki

Comparative speaking, shouting and singing voice range profile measurement: Physiological and pathological aspects. Logoped Phoniatr Vocol 1996; 21(3–4): 123–129.

19.

Ramig

Countryman

O’Brien

, et al. Intensive speech treatment for patients with Parkinson disease: Short and long-term comparison of two techniques. Neurology 1996; 47: 1496–1504.

20.

Fox

Morrison

Ramig

, et al. Current perspectives on the Lee Silverman Voice Treatment (LSVT®). Am J Speech Lang Pathol 2002; 11: 111–123.

21.

Maas

Robin

Austermann Hula

, et al. Principles of motor learning in treatment of motor speech disorders. Am J Speech Lang Pathol 2008; 17(3): 277–298.

22.

Jacobson

Johnson

Grywalski

, et al. The Voice Handicap Index (VHI): Development and validation. Am J Speech Lang Pathol 1997; 6(3): 66–70.

23.

Hirano

. Psycho-acoustic evaluation of voice. In: Hirano

(ed.) Clinical examination of voice. New York: Springer-Verlag, 1981, pp. 81–84.

24.

De Biagi

Heikkola

Nordio

, et al. Update on recent developments in communication and swallowing in multiple sclerosis. Int J MS Care 2020; 22(6): 270–275.

25.

Wight

Miller

Lee Silverman Voice Treatment for people with Parkinson’s: Audit of outcomes in a routine clinic. Int J Lang Commun Disord 2015; 50(2): 215–225.

26.

Fatigue Guidelines Development Panel of the Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and multiple sclerosis. Evidence-based management strategies for fatigue in multiple sclerosis. Washington, DC: Paralyzed Veterans of America, 1998.

27.

Kos

Kerckhofs

Carrea

, et al. Evaluation of the modified fatigue impact scale in four different European countries. Mult Scler 2005; 11(1): 76–80.

28.

Ramig

Sapir

Fox

, et al. Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson’s disease: A comparison with untreated patients and normal age-matched controls. Mov Disord 2001; 16(1): 79–83.

29.

Ramig

Halpern

Spielman

, et al. Speech treatment in Parkinson’s disease: Randomized controlled trial (RCT). Mov Disord 2018; 33(11): 1777–1791.

30.

Ramig

Sapir

Countryman

, et al. Intensive voice treatment (LSVT) for patients with Parkinson’s disease: A 2 year follow up. J Neurol Neurosurg Psychiatry 2001; 71(4): 493–498.

31.

Amatya

Khan

Galea

Rehabilitation for people with multiple sclerosis: An overview of Cochrane Reviews. Cochrane Database Syst Rev 2019; 1: CD012732.

32.

Burtscher

Millet

GP.

(Indoor) isolation, stress, and physical inactivity: Vicious circles accelerated by COVID-19?

Scand J Med Sci Sports 2020; 30(8): 1544–1545.

33.

Bryans

Palmer

Anderson

, et al. The impact of Lee Silverman Voice Treatment (LSVT LOUD®) on voice, communication, and participation: Findings from a prospective, longitudinal study. J Commun Disord 2021; 89: 106031.

34.

Niebudek-Bogusz

Kuzańska

Woznicka

, et al. Assessment of the voice handicap index as a screening tool in dysphonic patients. Folia Phoniatr Logop 2011; 63(5): 269–272.

35.

Speyer

Bogaardt

Passos

, et al. Maximum phonation time: Variability and reliability. J Voice 2010; 24(3): 281–284.

36.

Maslan

Leng

Rees

, et al. Maximum phonation time in healthy older adults. J Voice 2011; 25(6): 709–713.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB

0.02 MB

0.55 MB

Effects of voice rehabilitation in people with MS: A double-blinded long-term randomized controlled trial

Abstract

Background:

Objective:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material